216 related articles for article (PubMed ID: 25188816)
1. Fibroblast growth factor receptor inhibition is active against mesothelioma and synergizes with radio- and chemotherapy.
Schelch K; Hoda MA; Klikovits T; Münzker J; Ghanim B; Wagner C; Garay T; Laszlo V; Setinek U; Dome B; Filipits M; Pirker C; Heffeter P; Selzer E; Tovari J; Torok S; Kenessey I; Holzmann K; Grasl-Kraupp B; Marian B; Klepetko W; Berger W; Hegedus B; Grusch M
Am J Respir Crit Care Med; 2014 Oct; 190(7):763-72. PubMed ID: 25188816
[TBL] [Abstract][Full Text] [Related]
2. The inhibition of FGF receptor 1 activity mediates sorafenib antiproliferative effects in human malignant pleural mesothelioma tumor-initiating cells.
Pattarozzi A; Carra E; Favoni RE; Würth R; Marubbi D; Filiberti RA; Mutti L; Florio T; Barbieri F; Daga A
Stem Cell Res Ther; 2017 May; 8(1):119. PubMed ID: 28545562
[TBL] [Abstract][Full Text] [Related]
3. Expression of FGFR1-4 in Malignant Pleural Mesothelioma Tissue and Corresponding Cell Lines and its Relationship to Patient Survival and FGFR Inhibitor Sensitivity.
Vlacic G; Hoda MA; Klikovits T; Sinn K; Gschwandtner E; Mohorcic K; Schelch K; Pirker C; Peter-Vörösmarty B; Brankovic J; Dome B; Laszlo V; Cufer T; Rozman A; Klepetko W; Grasl-Kraupp B; Hegedus B; Berger W; Kern I; Grusch M
Cells; 2019 Sep; 8(9):. PubMed ID: 31527449
[TBL] [Abstract][Full Text] [Related]
4. Nonamplified FGFR1 is a growth driver in malignant pleural mesothelioma.
Marek LA; Hinz TK; von Mässenhausen A; Olszewski KA; Kleczko EK; Boehm D; Weiser-Evans MC; Nemenoff RA; Hoffmann H; Warth A; Gozgit JM; Perner S; Heasley LE
Mol Cancer Res; 2014 Oct; 12(10):1460-9. PubMed ID: 24966347
[TBL] [Abstract][Full Text] [Related]
5. Temsirolimus inhibits malignant pleural mesothelioma growth in vitro and in vivo: synergism with chemotherapy.
Hoda MA; Mohamed A; Ghanim B; Filipits M; Hegedus B; Tamura M; Berta J; Kubista B; Dome B; Grusch M; Setinek U; Micksche M; Klepetko W; Berger W
J Thorac Oncol; 2011 May; 6(5):852-63. PubMed ID: 21358348
[TBL] [Abstract][Full Text] [Related]
6. Combined MEK and PI3K/p110β Inhibition as a Novel Targeted Therapy for Malignant Mesothelioma Displaying Sarcomatoid Features.
Marqués M; Tranchant R; Risa-Ebrí B; Suárez-Solís ML; Fernández LC; Carrillo-de-Santa-Pau E; Del Pozo N; Martínez de Villarreal J; Meiller C; Allory Y; Blum Y; Pirker C; Hegedus B; Barry ST; Carnero A; Berger W; Jean D; Real FX
Cancer Res; 2020 Feb; 80(4):843-856. PubMed ID: 31911549
[TBL] [Abstract][Full Text] [Related]
7. Trabectedin Is Active against Malignant Pleural Mesothelioma Cell and Xenograft Models and Synergizes with Chemotherapy and Bcl-2 Inhibition In Vitro.
Hoda MA; Pirker C; Dong Y; Schelch K; Heffeter P; Kryeziu K; van Schoonhoven S; Klikovits T; Laszlo V; Rozsas A; Ozsvar J; Klepetko W; Döme B; Grusch M; Hegedüs B; Berger W
Mol Cancer Ther; 2016 Oct; 15(10):2357-2369. PubMed ID: 27512118
[TBL] [Abstract][Full Text] [Related]
8. JQ1, a BET Inhibitor, Synergizes with Cisplatin and Induces Apoptosis in Highly Chemoresistant Malignant Pleural Mesothelioma Cells.
Zanellato I; Colangelo D; Osella D
Curr Cancer Drug Targets; 2018; 18(8):816-828. PubMed ID: 28669341
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive Pharmacogenomic Profiling of Malignant Pleural Mesothelioma Identifies a Subgroup Sensitive to FGFR Inhibition.
Quispel-Janssen JM; Badhai J; Schunselaar L; Price S; Brammeld J; Iorio F; Kolluri K; Garnett M; Berns A; Baas P; McDermott U; Neefjes J; Alifrangis C
Clin Cancer Res; 2018 Jan; 24(1):84-94. PubMed ID: 29061644
[No Abstract] [Full Text] [Related]
10. Co-active receptor tyrosine kinases mitigate the effect of FGFR inhibitors in FGFR1-amplified lung cancers with low FGFR1 protein expression.
Kotani H; Ebi H; Kitai H; Nanjo S; Kita K; Huynh TG; Ooi A; Faber AC; Mino-Kenudson M; Yano S
Oncogene; 2016 Jul; 35(27):3587-97. PubMed ID: 26549034
[TBL] [Abstract][Full Text] [Related]
11. PI3 Kinase Pathway and MET Inhibition is Efficacious in Malignant Pleural Mesothelioma.
Kanteti R; Riehm JJ; Dhanasingh I; Lennon FE; Mirzapoiazova T; Mambetsariev B; Kindler HL; Salgia R
Sci Rep; 2016 Sep; 6():32992. PubMed ID: 27623107
[TBL] [Abstract][Full Text] [Related]
12. Assessment of signaling pathway inhibitors and identification of predictive biomarkers in malignant pleural mesothelioma.
Tranchant R; Quetel L; Montagne F; De Wolf J; Meiller C; De Koning L; Le Pimpec-Barthes F; Zucman-Rossi J; Jaurand MC; Jean D
Lung Cancer; 2018 Dec; 126():15-24. PubMed ID: 30527180
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of FGFR2 and FGFR1 increases cisplatin sensitivity in ovarian cancer.
Cole C; Lau S; Backen A; Clamp A; Rushton G; Dive C; Hodgkinson C; McVey R; Kitchener H; Jayson GC
Cancer Biol Ther; 2010 Sep; 10(5):495-504. PubMed ID: 20595807
[TBL] [Abstract][Full Text] [Related]
14. Merlin deficiency predicts FAK inhibitor sensitivity: a synthetic lethal relationship.
Shapiro IM; Kolev VN; Vidal CM; Kadariya Y; Ring JE; Wright Q; Weaver DT; Menges C; Padval M; McClatchey AI; Xu Q; Testa JR; Pachter JA
Sci Transl Med; 2014 May; 6(237):237ra68. PubMed ID: 24848258
[TBL] [Abstract][Full Text] [Related]
15. Cisplatin unleashes Toll-like receptor 3-mediated apoptosis through the downregulation of c-FLIP in malignant mesothelioma.
Vanbervliet-Defrance B; Delaunay T; Daunizeau T; Kepenekian V; Glehen O; Weber K; Estornes Y; Ziverec A; Djemal L; Delphin M; Lantuéjoul S; Passot G; Grégoire M; Micheau O; Blanquart C; Renno T; Fonteneau JF; Lebecque S; Mahtouk K
Cancer Lett; 2020 Mar; 472():29-39. PubMed ID: 31838086
[TBL] [Abstract][Full Text] [Related]
16. In Vitro and In Vivo Antitumor Activity of [Pt(O,O'-acac)(γ-acac)(DMS)] in Malignant Pleural Mesothelioma.
Muscella A; Vetrugno C; Cossa LG; Antonaci G; De Nuccio F; De Pascali SA; Fanizzi FP; Marsigliante S
PLoS One; 2016; 11(11):e0165154. PubMed ID: 27806086
[TBL] [Abstract][Full Text] [Related]
17. Resistance mediated by alternative receptor tyrosine kinases in FGFR1-amplified lung cancer.
Adachi Y; Watanabe K; Kita K; Kitai H; Kotani H; Sato Y; Inase N; Yano S; Ebi H
Carcinogenesis; 2017 Oct; 38(11):1063-1072. PubMed ID: 28968756
[TBL] [Abstract][Full Text] [Related]
18. A link between the fibroblast growth factor axis and the miR-16 family reveals potential new treatment combinations in mesothelioma.
Schelch K; Kirschner MB; Williams M; Cheng YY; van Zandwijk N; Grusch M; Reid G
Mol Oncol; 2018 Jan; 12(1):58-73. PubMed ID: 29094504
[TBL] [Abstract][Full Text] [Related]
19. Urokinase-type plasminogen activator receptor promotes proliferation and invasion with reduced cisplatin sensitivity in malignant mesothelioma.
Wang S; Jiang L; Han Y; Chew SH; Ohara Y; Akatsuka S; Weng L; Kawaguchi K; Fukui T; Sekido Y; Yokoi K; Toyokuni S
Oncotarget; 2016 Oct; 7(43):69565-69578. PubMed ID: 27602956
[TBL] [Abstract][Full Text] [Related]
20. ADP sensitizes ZL55 cells to the activity of cisplatin.
Muscella A; Cossa LG; Vetrugno C; Antonaci G; Marsigliante S
J Cell Physiol; 2019 Apr; 234(4):4409-4417. PubMed ID: 30144378
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
